Abstract
This review summarises the key clinical features of septo-optic dysplasia (SOD), the significant inroads that progress in genetics has made into our understanding of the aetiology of the condition over the last decade, and the pitfalls and challenges that we face in the management of these phenotypically variable patients.
Similar content being viewed by others
In brief
-
Incidence 1 in 10 000 live births.1
-
Associated with younger maternal age.2
-
Phenotypically variable disorder.
-
Early forebrain developmental abnormality.
-
Diagnosed on a clinical basis, with ongoing debate as to the exact diagnostic criteria.
-
SOD can be caused by mutations in HESX1 and SOX2.3–6
-
A genetic diagnosis can currently be made in <1% of the patients.7,8
-
Associated features include developmental delay, seizures, visual impairment, sleep disturbance, precocious puberty, obesity, anosmia, sensorineural hearing loss and cardiac anomalies.
Introduction
The diagnosis of septo-optic dysplasia (SOD) is a clinical one and can be made when two or more features of the classical triad of (i) optic nerve hypoplasia, (ii) pituitary hormone abnormalities and (iii) midline brain defects, including agenesis of the septum pellucidum and/or corpus callosum, are present.9 It is a rare congenital anomaly, equally prevalent in males and females, and more common in infants born to younger mothers, with a reported incidence of 1 in 10 000 live births.1, 10
Clinical overview
Septo-optic dysplasia, previously termed de Morsier syndrome, was first described by Reeves in 1941 as an absence of the septum pellucidum in association with optic nerve abnormalities.11, 12 Subsequently, an association with pituitary dysfunction was described.13 Classically the diagnosis of SOD can be made clinically when two or more features of the classical triad (see above) are present. Morishima and Aranoff14 cite that ∼30% of SOD cases have complete manifestations, 62% have the complication of hypopituitarism and 60% have an absent septum pellucidum. Isolated features of the triad do not fulfil the diagnostic criteria for SOD, although debate is ongoing as to whether they represent milder cases of the SOD spectrum.15 The heterogeneous nature of the condition and the variable association with different clinical features led Polizzi et al16 to suggest that SOD should be renamed SOD complex. Debate is ongoing regarding the correct nomenclature, but for the purposes of this review article, we shall use the classical definition of SOD outlined above.17
There is a wide variation in the severity of the clinical features found, and in their association with other diagnoses, which follows no clear pattern (Figure 1). The main reported clinical findings are hypopituitarism (62–80%), with growth hormone deficiency being the commonest endocrine abnormality, visual impairment (23% significant visual impairment) and developmental delay (more common in children with bilateral (57%) as opposed to unilateral optic nerve hypoplasia (32%)).18 Seizures, developmental delay and cerebral palsy are the most frequent neurological associations.19 Pituitary hormone insufficiencies may evolve over time necessitating life-long medical follow-up.
Diagnostic approaches
Septo-optic dysplasia can present at birth in association with multiple congenital abnormalities or much later on when growth failure occurs in a child also noted to have visual abnormalities (although not necessarily as may just have growth failure with mild undetected visual abnormalities).15 The child may present with strabismus, nystagmus, or other visual abnormalities. In the majority of cases, the earlier the diagnosis is made the better the outcome, as untreated hormonal abnormalities place an additional neurodevelopmental burden on a child already compromised by visual impairment, and also place the patient at risk of hypoglycaemia, adrenal crises and consequently death. Clinically the diagnosis should be suspected in newborns with hypoglycaemia, jaundice, a microphallus with or without undescended testes and nystagmus with or without associated midline abnormalities such as cleft palate. In these infants, baseline endocrine tests should be performed as outlined below and an ophthalmology referral made. MRI brain images in conjunction with dynamic studies of pituitary function can then be used to confirm the diagnosis. Hormonal insufficiencies should be treated, and early referral both to a neurodevelopmental team with an interest in visual impairment and to a tertiary centre with expertise in managing these children made. A summary of key points to note while taking the history, undertaking ophthalmology assessment, interpreting MRI brain images and investigating pituitary function are outlined below.
Associated features to ask about when taking history
-
1
Consanguinity.
-
2
Hearing abnormality – sensorineural.
-
3
Developmental delay.
-
4
Anosmia.
-
5
Other congenital anomalies such as cardiac, oesophageal atresia and micropenis.
-
6
Seizures – commonly related to underlying abnormality of the brain anatomy, important to rule out hypoglycaemia as a cause.
-
7
Stereotypical behaviours – for example, mannerisms suggestive of a diagnosis of autistic spectrum disorder.
-
8
Sleep disorder – arrhythmicity.20
-
9
Excessive appetite.
-
10
Temperature instability.
-
11
Symptoms suggestive of hormonal deficiencies such as fatigue, polyuria and polydipsia, constipation, dry skin, hair loss and sweating.
Ophthalmology
-
1
Is there strabismus or nystagmus, and if so is it unilateral or bilateral?
-
2
Perform ophthalmological examination to identify clinical signs of ONH, which include a double-ring sign, pale and/or small optic discs/neuroretinal rim area.
-
3
Are optic nerve hypoplasia or dysplasia, microphthalmia, coloboma and/or other ophthalmological signs present?
-
4
Assess degree of visual impairment.
MRI of the brain
-
1
Are hypothalamo-pituitary axis appearances normal, checking specifically for:
-
a)
Anterior pituitary size.
-
b)
Presence and location of posterior pituitary.
-
c)
Presence and thickness of infundibulum.
-
a)
-
2
Is the septum pellucidum present?
-
3
Are the optic nerves and chiasm normal?
-
4
Is the appearance of the corpus callosum normal?
-
5
Are there any other associated brain abnormalities such as schizencephaly, cavum septum pellucidum, cerebellar hypoplasia and aplasia of the fornix.
Classically MRI brain images show hypoplasia of the optic nerves (unilateral or bilateral) and optic chiasm, agenesis of the septum pellucidum, abnormalities of the corpus callosum and hypothalamo-pituitary axis (Figure 2). However, MRI findings vary considerably between patients.21
Tests of pituitary function
-
1
Thyroid function (low TSH of secondary hypothyroidism may be missed by neonatal screening).
-
2
Cortisol
-
a)
Random cortisol sufficient in neonate, 8 am cortisol appropriate in individuals aged >1 year.
-
b)
If abnormal cortisol, proceed to synacthen test or 24-h cortisol and glucose profile.
-
a)
-
3
Growth hormone
-
a)
Ask for symptoms of hypoglycaemia and measure glucose profile on adequate hydrocortisone replacement. If hypoglycaemia detected measure IGF-1 and IGFBP-3, and consider GH replacement.
-
b)
Monitor growth and if poor growth velocity measure GH response to provocation testing in patients over the age of one year.
-
a)
-
4
Monitor pubertal status – SOD can be associated with precocious puberty secondary to hypothalamic dysfunction, or hypogonadotrophic hypogonadism secondary to LH and FSH deficiency.
-
5
Ask about fluid intake: if excessive, measure paired fasting plasma and urine osmolalities; may need to perform water deprivation test to confirm diagnosis of diabetes insipidus.
Molecular and genetic basis of the disease
The association of abnormalities of the forebrain found in SOD is likely to reflect an early forebrain developmental abnormality, occurring at 4–6 weeks of gestation, a critical period of morphogenesis for the anterior neural plate. Improved understanding of the development of the pituitary gland and forebrain, and the identification of transcription factors important in this process has led to the discovery of genes (so far only two), which when mutated cause SOD. HESX1, a paired-like homeobox gene, which acts as a transcriptional repressor, is one of the earliest markers of murine pituitary development. The study of Hesx1 null mice identified it as a possible candidate gene for SOD, and subsequent investigation of the human homologue HESX1 (OMIM 601802) has led to the identification of five homozygous (autosomal recessive inheritance) and eight heterozygous (autosomal dominant inheritance) pathogenic mutations3, 4 (Table 1). The homozygous mutations are fully penetrant, whereas heterozygous mutations are variably penetrant and usually associated with a milder phenotype.22, 23 Mutations have also been identified in SOX2 in association with severe bilateral eye abnormalities (anophthalmia, microphthalmia) and defects of the corpus callosum with anterior pituitary hypoplasia.24 Additional features described in association with SOX2 mutations include developmental delay, short stature, oesophageal atresia, male genital tract abnormalities and sensorineural hearing loss.25
Establishing the genotype not only furthers our understanding of the aetiology of SOD but also aids patient management, enabling accurate genetic counseling and early diagnosis.
Currently genetic abnormalities are identified in <1% of the patients, with the aetiology of SOD remaining unclear in the majority of patients. This has led to debate as to other factors, which may also have a role in the pathogenesis of SOD. Many studies have reported an increased prevalence of antenatal drug and alcohol abuse and younger maternal age in SOD cohorts.2, 26 This in combination with the pattern of neurological abnormalities found in individuals with SOD led Lubinsky27 to suggest that septo-optic dysplaisa occurs secondary to a vascular disruption sequence.28 It is likely that although other genetic abnormalities are likely to be identified in the future, environmental factors such as drugs, alcohol and anterior cerebral artery supply during the neonatal period may also play a significant role in the aetiology of SOD.
Management
Patients with SOD need regular (at least six-monthly) ongoing follow-up by a multi-disciplinary team. Management centres on identifying evolving hormonal insufficiencies and optimising hormonal replacement, ensuring appropriate ophthalmological follow-up, instigating neurodevelopmental support early on in life from a team with experience in looking after children with visual impairment, and monitoring closely for the development of other associated features such as autism and obesity.
Genetic counseling
The majority of cases of SOD are sporadic, and therefore, in the absence of any family history of the disorder, the recurrence risk is <1%. In consanguineous families, the likelihood of recessive inheritance is significantly higher, and parents should be counseled that even if there is no identifiable genetic mutation, the likely recurrence risk is one in four. SOX2 mutations are de novo with a very low risk of recurrence. The variable penetrance and phenotypes associated with dominant HESX1 mutations make genetic counseling difficult, as it would be impossible to predict whether the mutations would be associated with a distinct phenotype.
Conclusion
Septo-optic dysplasia remains a rare, heterogeneous and phenotypically variable disorder, which can pose significant diagnostic challenges; namely, the delay in diagnosis, the later development of hormonal deficiencies and the presence of other phenotypic features such as obesity and autism. Challenges such as this highlight the need for the careful longitudinal follow-up of large patient cohorts, to enable the development of more accurate diagnostic criteria and ongoing management plans.
Research is ongoing into the genetic aetiology of SOD. To date, the overall frequency of pathological genetic mutations identified in the SOD population is low, with no mutations identified in many familial cases, suggesting that mutations in other known or unknown genes may have a role in this complex disorder. Our knowledge and understanding of the transcriptional factors involved in the development of the forebrain remains rudimentary and future work identifying these may uncover other molecular causes for SOD. The multi-faceted interaction between these transcription factors and the environment is also likely to play a role in the significant variability in phenotype and penetrance associated with SOD.1, 31 Further investigation of these intricate relationships may help us to better understand the aetiology of this complex disorder, possibly enabling us in the future to develop an improved diagnostic algorithm and to predict which children are likely to go on to develop hormonal abnormalities, developmental problems, and so on.
References
Patel L, McNally RJ, Harrison E et al: Geographical distribution of optic nerve hypoplasia and septo-optic dysplasia in Northwest England. J Pediatr 2006; 148: 85–88.
Lippe B, Kaplan SA, LaFranchi S : Septo-optic dysplasia and maternal age. Lancet 1979; 2: 92–93.
Dattani MT, Martinez-Barbera JP, Thomas PQ et al: Mutations in the homeobox gene HESX1/Hesx1 associated with septo-optic dysplasia in human and mouse. Nat Genet 1998; 19: 125–133.
Kelberman D, Rizzoti K, Avilion A et al: Mutations within Sox2/SOX2 are associated with abnormalities in the hypothalamo-pituitary-gonadal axis in mice and humans. J Clin Invest 2006; 116: 2442–2455.
Kelberman D, de Castro SC, Huang S et al: SOX2 plays a critical role in the pituitary, forebrain and eye during human embryonic development. J Clin Endocrinol Metab 2008; 93: 1865–1873.
Sato N, Kamachi Y, Kondoh H et al: Hypogonadotropic hypogonadism in an adult female with a heterozygous hypomorphic mutation of SOX2. Eur J Endocrinol 2007; 156: 167–171.
Kelberman D, Dattani MT : Septo-optic dysplasia – novel insights into the aetiology. Horm Res 2008; 69: 257–265.
McNay DE, Turton JP, Kelberman D et al: HESX1 mutations are an uncommon cause of septooptic dysplasia and hypopituitarism. J Clin Endocrinol Metab 2007; 92: 691–697.
Kelberman D, Dattani MT : Genetics of septo-optic dysplasia. Pituitary 2007; 10: 393–407.
Elster AB, McAnarney ER : Maternal age re septo-optic dysplasia. J Pediatr 1979; 94: 162–163.
Reeves DL : Congenital absence of the septum pellucidum. Bull Johns Hopkins Hosp 1941; 69: 61–71.
De Morsier G : Studies on malformation of cranio-encephalic sutures. III. Agenesis of the septum lucidum with malformation of the optic tract. Schweiz Arch Neurol Psychiatr 1956; 77: 267–292.
Hoyt WF, Kaplan SL, Grumbach MM et al: Septo-optic dysplasia and pituitary dwarfism. Lancet 1970; 1: 893–894.
Morishima A, Aranoff GS : Syndrome of septo-optic-pituitary dysplasia: the clinical spectrum. Brain Dev 1986; 8: 233–239.
Hellstrom A, Aronsson M, Axelson C et al: Children with septo-optic dysplasia – how to improve and sharpen the diagnosis. Horm Res 2000; 53 (Suppl1): 19–25.
Polizzi A, Pavone P, Iannetti P et al: Septo-optic dysplasia complex: a heterogeneous malformation syndrome. Pediatr Neurol 2006; 34: 66–71.
Barkovich AJ, Fram EK, Norman D : Septo-optic dysplasia: MR imaging. Radiology 1989; 171: 189–192.
Haddad NG, Eugster EA : Hypopituitarism and neurodevelopmental abnormalities in relation to central nervous system structural defects in children with optic nerve hypoplasia. J Pediatr Endocrinol Metab 2005; 18: 853–858.
Garcia ML, Ty EB, Taban M et al: Systemic and ocular findings in 100 patients with optic nerve hypoplasia. J Child Neurol 2006; 21: 949–956.
Rivkees SA : Arrhythmicity in a child with septo-optic dysplasia and establishment of sleep-wake cyclicity with melatonin. J Pediatr 2001; 139: 463–465.
Mehta A, Hindmarsh PC, Mehta H et al: Congenital hypopituitarism: clinical, molecular and neuroradiological correlates. Clin Endocrinol, e-pub ahead of print, 6 March 2009.
Thomas PQ, Dattani MT, Brickman JM et al: Heterozygous HESX1 mutations associated with isolated congenital pituitary hypoplasia and septo-optic dysplasia. Hum Mol Genet 2001; 10: 39–45.
Cohen RN, Cohen LE, Botero D et al: Enhanced repression by HESX1 as a cause of hypopituitarism and septooptic dysplasia. J Clin Endocrinol Metab 2003; 88: 4832–4839.
Alatzoglou KS, Kelberman D, Dattani MT : The role of SOX proteins in normal pituitary development. J Endocrinol 2009; 200: 245–258.
Hagstrom SA, Pauer GJT, Reid J et al: SOX2 mutation causes anophthalmia, hearing loss, and brain anomalies. Am J Med Genet A 2005; 138A: 95–98.
Riedl S, Vosahlo J, Battelino T et al: Refining clinical phenotypes in septo-optic dysplasia based on MRI findings. Eur J Pediatr 2008; 167: 1269–1276.
Lubinsky MS : Hypothesis: septo-optic dysplasia is a vascular disruption sequence. Am J Med Genet 1997; 69: 235–236.
Stevens CA, Dobyns WB : Septo-optic dysplasia and amniotic bands: further evidence for a vascular pathogenesis. Am J Med Genet A 2004; 125A: 12–16.
Carvalho LR, Woods KS, Mendonca BB et al: A homozygous mutation in HESX1 is associated with evolving hypopituitarism due to impaired repressor-corepressor interaction. J Clin Invest 2003; 112: 1192–1201.
Tajima T, Hattorri T, Nakajima T et al: Sporadic heterozygous frameshift mutation of HESX1 causing pituitary and optic nerve hypoplasia and combined pituitary hormone deficiency in a Japanese patient. J Clin Endocrinol Metab 2003; 88: 45–50.
Coya R, Vela A, Perez de Nanclares G et al: Panhypopituitarism: genetic versus acquired etiological factors. J Pediatr Endocrinol Metab 2007; 20: 27–36.
Sobrier ML, Maghnie M, Vie-Luton MP et al: Novel HESX1 mutations associated with a life-threatening neonatal phenotype, pituitary aplasia, but normally located posterior pituitary and no optic nerve abnormalities. J Clin Endocrinol Metab 2006; 91: 4528–4536.
Sobrier ML, Netchine I, Heinrichs C et al: Alu-element insertion in the homeodomain of HESX1 and aplasia of the anterior pituitary. Hum Mutat 2005; 25: 503.
Zenteno JC, Gascon-Guzman G, Tovilla-Canales JL : Bilateral anophthalmia and brain malformations caused by a 20-bp deletion in the SOX2 gene. Clin Genet 2005; 68: 564–566.
Williamson KA, Hever AM, Rainger J et al: Mutations in SOX2 cause anophthalmia-esophageal-genital (AEG) syndrome. Hum Mol Genet 2006; 15: 1413–1422.
Bakrania P, Robinson DO, Bunyan DJ et al: SOX2 anophthalmia syndrome: 12 new cases demonstrating broader phenotype and high frequency of large gene deletions. Br J Ophthalmol 2007; 91: 1471–1476.
Andoniadou CL, Signore M, Sajedi E et al: Lack of the murine homeobox gene Hesx1 leads to a posterior transformation of the anterior forebrain. Development 2007; 134: 1499–1508.
Martinez-Barbera JP, Rodriguez TA, Beddington RS : The homeobox gene Hesx1 is required in the anterior neural ectoderm for normal forebrain formation. Dev Biol 2000; 223: 422–430.
Martinez-Barbera JP, Beddington RS : Getting your head around Hex and Hesx1: forebrain formation in mouse. Int J Dev Biol 2001; 45: 327–336.
Sajedi E, Gaston-Massuet C, Signore M et al: Analysis of mouse models carrying the I26T and R160C substitutions in the transcriptional repressor HESX1 as models for septo-optic dysplasia and hypopituitarism. Dis Model Mech 2008; 1: 241–254.
Further reading
The last four references (37–40) are for further references.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Webb, E., Dattani, M. Septo-optic dysplasia. Eur J Hum Genet 18, 393–397 (2010). https://doi.org/10.1038/ejhg.2009.125
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ejhg.2009.125
Keywords
This article is cited by
-
Neurodevelopmental impairments in children with septo-optic dysplasia spectrum conditions: a systematic review
Molecular Autism (2023)
-
Major brain malformations: corpus callosum dysgenesis, agenesis of septum pellucidum and polymicrogyria in patients with BCORL1-related disorders
Journal of Human Genetics (2022)
-
Hypothalamic syndrome
Nature Reviews Disease Primers (2022)
-
Advances in differential diagnosis and management of growth hormone deficiency in children
Nature Reviews Endocrinology (2021)
-
‘Pseudo-septum’ Appearance in Septal Agenesis on Fetal MRI
Journal of Fetal Medicine (2021)